Yükleniyor... / Loading...
This study evaluated the safety and how the body processes (pharmacokinetics) the drug PF-06651600 in healthy volunteers. Participants received PF-06651600 or placebo; healthy men and women aged 18 to 55 were assessed. It was conducted in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Healthy male/female subjects between 18 and 55 years old, inclusive. Females must be of non-child bearing potential. * BMI of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). * Evidence of personally signed and dated informed consent document. * Willing and able to comply with scheduled visits, treatment plan, lab tests and other study procedures. * Subjects must avoid high intensity UV light exposure (eg, active sunbathing, tanning beds/booths or sunlamps) from the first dose of study drug and for the duration of the study. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, GI, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. * Use of tobacco/nicotine containing products in excess of 5 cigarettes/day. * History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males. * Screening blood pressure \>140/90 mm Hg. * Screening laboratory abnormalities as defined by the protocol. * Unwilling or unable to comply with the Lifestyle Guidelines as defined by the protocol.